The safety and tolerability of donepezil in patients with Alzheimer's disease

British Journal of Clinical Pharmacology, Supplement

Volumn 58, Issue 1, 2004, Pages 1-8

  Jackson, Stephen ^a   Ham, Richard J ^b   Wilkinson, David ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c MOORGREEN HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Donepezil

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIGOXIN; DONEPEZIL; GALANTAMINE; HALOPERIDOL; KETOCONAZOLE; NEUROLEPTIC AGENT; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RISPERIDONE; RIVASTIGMINE; SUXAMETHONIUM; TACRINE; THEOPHYLLINE; VITAMIN; WARFARIN; ACETYLCHOLINESTERASE;

ALZHEIMER DISEASE; ANOREXIA; ASTHENIA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOTOXICITY; CHOLINERGIC ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART BLOCK; HUMAN; IN VITRO STUDY; INCIDENCE; INSOMNIA; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; MULTIINFARCT DEMENTIA; NAUSEA; PRIORITY JOURNAL; PUBLICATION; REVIEW; SLEEP DISORDER; SYNCOPE; VOMITING; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; CHOLINESTERASE INHIBITION; DRUG DOSE REGIMEN; DRUG RESPONSE; GASTROINTESTINAL DISEASE; MULTIPLE DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 8844256158     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.01848.x     Document Type: Review

References (73)

1. Ames DJ, Bhathal PS, Davies BM, Fraser JR, Gibson PR, Roberts S. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Aust N Z J Med 1990; 20: 193-5.
2. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-8.
3. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91.
4. Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev 2001; 2: CDOO1499.
5. Kumar V. Introduction to cholinesterase inhibitors used in Alzheimer's disease therapy. In Alzheimer Disease: Therapeutic Strategies, eds Giacobini E, Becker R, Boston: Birkhäuser, 1994: 99-102.
6. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet 1998; 35: 49-64.
7. Volicer L, Hurley AC. Physical status and complications in patients with Alzheimer disease: implications for outcome studies. Alzheimer Dis Assoc Disord 1997; 11(Suppl. 6): 60-5.
8. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 10): 1-6.
9. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 7-12.
10. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
11. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-31.
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45.
13. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
14. Whitehead A, Perdomo C, Pratt R, Birks J, Wilcock G, Grimley-Evans J. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004; 19: 624-33.
15. O'Brien JT, Ballard CG. Drugs for Alzheimer's disease, cholinesterase inhibitors have passed NICE's hurdle. BMJ 2001; 323: 123-4.
16. Corey-Bloom J, Anand R, Veach J for the ENA713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
17. Rosier M, Retz W, Retz-Junginger P, Dennler H. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998; 11: 211-16.
18. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
19. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD - a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-78.
20. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76.
21. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
22. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
23. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
24. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003; 51: 937-44.
25. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72: 310-14
26. Pratt RD, Perdomo CA, Surick IW, Ieni JR. Donepezil: tolerability and safety in Alzheimer's disease. Int J Clin Pract 2002; 56: 710-17.
27. Dronfield S, Egan K, Marsden CA, Green AR. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripherally cholinergically mediated responses in the rat. J Psychopharmacol 2000; 14: 275-9.
28. Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, Shalaby IA, Ramirez A, Nason D, White WF. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol 2004; 486: 9-17.
29. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56: 441-6.
30. Reminyl® (galantamine HBr). Reminyl® (US package insert), March 2001. Titusville, NJ, USA: Janssen.
31. Aricept® (donepezil hydrochloride tablets). Aricept® (US package insert), December 2001. Teaneck, NJ, USA: Eisai Inc.
32. Exelon® (rivastigmine tartrate). Exelon® (US package insert), June 2001. East Hanover, NJ, USA: Novartis Pharmaceuticals Corporation.
33. Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, Tesfaye Y, Saint-Martin M, Bacher Y, Carrier L, Charbonneau R, Clarfield AMM, Collier B, Dastoor D, Gauthier L, Germain M, Kissel C, Krieger M, Kushnir S, Masson H, Morin J, Nair V, Neirinck L, Suissa S. Tetrahydroaminoacridine- lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990; 322: 1272-6.
34. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. The Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-9.
35. Wood PC, Castleden M. A double-blind, placebo-controlled, multicentre study of tacrine for Alzheimer's disease. Int J Geriatr Psychiatry 1994; 9: 649-54.
36. Sugimoto H, Limura Y, Yamanishi Y, Yamatsu K. Synthesis and anticholinesterase activity of 1-benzyl-4-[(5,6,-dimethoxy-1-indanon-2-yl) methyl]piperidine hydrochloride (E2020) and related compounds. Bioorg Medical Chem Lett 1992; 2: 871-6.
37. Ford JM, Truman CA, Wilcock GK, Roberts CJ. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 1993; 53: 691-5.
38. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001; 15: 375-90.
39. Galligan JJ, Burks TF. Cholinergic neurones mediate intestinal propulsion in the rat. J Pharm Exp Ther 1986; 238: 594-8.
40. Lewin MJ. Cellular mechanisms and inhibitors of gastric acid secretion. Drugs Today (Barc) 1999; 35: 743-52.
41. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-5.
42. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH. Donepezil therapy in clinical practice - a randomized crossover study. Arch Neurol 2000; 57: 94-9.
43. Matthews HP, Korbey J, Wilkinson DG, Rowden J. Donepezil in Alzheimer's disease: eighteen-month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000; 15: 713-20.
44. Hager K, Calabrese P, Frolich L, Gobel C, Berger FM. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 15: 189-98.
45. Boada-Rovira M, Brodaty H, Cras P, Baloyannis S, Emre M, Zhang R, Bahra R; 322 Study Group. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging 2004; 21: 43-53.
46. Relkin NR, Reichman WE, Orazem J, McRae T. A large community based, open-label trial of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 16: 15-24.
47. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 58-67.
48. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998; 46: 1223-7.
49. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-9.
50. Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001; 44: 161-82.
51. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD; Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479-86.
52. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-30.
53. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46(Suppl. 1): 13-18.
54. Monti JM, Monti D. Role of dorsal raphe nucleus serotonin 5-HT1A receptor in the regulation of REM sleep. Life Sci 2000; 66: 1999-2012.
55. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000; 55: 870-1.
56. Ross JS, Shua-Haim JR. Aricept-induced nightmares in Alzheimer's disease: 2 case reports. J Am Geriatr Soc 1998; 46: 119-20.
57. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging 2001; 18: 853-62.
58. Woodhouse K, Wynne HA. Age-related changes in hepatic function. Implications for drug therapy. Drugs Aging 1992; 2: 243-55.
59. Tiseo PJ, Vargas R, Perdomo CA, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. J Clin Pharmacol 1998; 46(Suppl. 1): 51-5.
60. Pugh RNH, Murray-Lyon IM, Danson JL, Pietroni MC, Willians R. Transection of the esophagus for bleeding esophageal varices. Br J Surg 1973; 40: 646-54.
61. Lubran MM. Renal function in the elderly. Ann Clin Laboratory Sci 1995; 25: 122-33.
62. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCL in patients with moderately to severely impaired renal function. Br J Clin Pharmacol 1998; 46(Suppl. 1): 56-60.
63. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 25-9.
64. VanDenBerg CM, Kazmi Y, Jann MW. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly. Drugs Aging 2000; 16: 123-38.
65. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCL and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 30-4.
66. Reyes JF, Preskorn SH, Khan A et al. Concurrent administration of donepezil HCL and risperidone in patients with schizophreria: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol; 58(Suppl. 1): 50-7.
67. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 147-51.
68. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46(Suppl. 1): 40-4.
69. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998; 46(Suppl. 1): 45-50.
70. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following a multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998; 46(Suppl. 1): 35-9.
71. Feldman S, Karalliedde L. Drug interactions with neuromuscular blockers. Drug Safety 1996; 15: 261-73.
72. Heath ML. Donepezil, Alzheimer's disease and suxamethonium. Anaesthesia 1997; 52: 1018.
73. Walker C, Perks D. Do you know about donepezil and succinylcholine? Anaesthesia 2002; 57: 1041.